Driving Innovation in Inhaled and Nasal Drug Product Development
Explore how Nanopharm, a globally recognized Contract Research Organization (CRO), is becoming the inevitable choice for inhalation and nasal drug product development. Under the leadership of Gemma Budd, the new General Manager, Nanopharm has established itself as a Centre of Excellence in Orally Inhaled and Nasal Drug Products (OINDP). With its state-of-the-art, purpose-built facility, Nanopharm offers comprehensive inhalation services, characterized by an in-depth understanding of OINDP science, products, and test methods.
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Simulation in In Vitro Bioequivalence for Particle Sizes
Explore Simulation-informed design in in-vitro bioequivalence trials for particle size distributions’ performance.
